Conisation is a surgery that removes abnormal cervical lesions---cervical intraepithelial neoplasia. Human papilloma virus (HPV) infection is associated with almost all cervical cancers; conisation is therefore a definitive marker of HPV infection ([@bib7]). HPV DNA (oncogenic subtypes 16 and 18) can transform normal breast cells into a growth factor-independent phenotype ([@bib5]). HPV DNA and koilocytes---hallmarks of HPV infection---have been identified in breast tumours ([@bib13], [@bib14]). HPV may therefore contribute to breast carcinogenesis, although the underlying biology is poorly understood ([@bib16]; [@bib27]). Most HPV cervical infections resolve untreated ([@bib10]), but persistent infection warranting treatment intervention may signify impaired immune function ([@bib1]).

Three meta-analyses have investigated the association between HPV infection and breast cancer (BC), including 9, 10, and 16 case--control studies, respectively ([@bib15]; [@bib21]; [@bib28]). The summary effect estimates suggested three- to six-fold increased BC incidence among women with HPV infection. Each called for large studies on HPV and BC incidence. The existing research has limited follow-up, small sample size, and no information on comorbid diseases, which may compromise immune function ([@bib4]). A large Norwegian study suggested a 10% increased risk of *in situ* and localised but not metastatic breast tumours among women with precancerous cervical lesions ([@bib8]).

Given the high incidence of BC in developed countries, any association between HPV and BC risk requires confirmation. We therefore conducted a large nationwide population-based study using prospectively collected data from Danish registries to investigate the association between cervical conisation as a marker of chronic HPV infection and risk of BC.

Materials and methods
=====================

The Danish National Health Service guarantees tax-supported health care for all residents. Health service utilisation is recorded in nationwide registries using each resident\'s unique personal identifier, which permits linkage across registries ([@bib19]). We used the Danish National Patient Registry (DNPR), covering all Danish hospitals ([@bib20]), to identify all women aged ⩾18 years who underwent cervical conisation during the study period ([Supplementary Appendix 1](#sup1){ref-type="supplementary-material"}). All surgical procedures are registered in the DNPR according to the 'Danish Classification of Surgical Procedures and Therapy\'. Inpatient diagnoses were available from 1978 to 1994 and both in and outpatient diagnoses thereafter. Through linkage to the Civil Registration System, which contains data on vital status and emigration ([@bib19]), and to the Danish Cancer Registry (DCR), which records information on all incident malignancies ([@bib25]), we followed women from their conisation date to incident BC, death, emigration, or 30 November 2013, whichever came first. We also retrieved information on cancer stage (localised *vs* non-localised disease). We used the Danish Pathology Registry ([@bib6]) to retrieve data on oestrogen receptor (ER) status at BC diagnosis among women who underwent conisation (1997 onwards when pathology data was available). We retrieved information from the DNPR on comorbidities diagnosed before conisation, and classified these using the Charlson Comorbidity Index (CCI) ([@bib2]). We used the DNPR to retrieve information on clinical diagnoses of autoimmune disease, obesity and alcohol-related disease ([Supplementary Appendix 1](#sup1){ref-type="supplementary-material"}).

We computed the expected number of BCs using national incidence rates by age (1-year bands) and diagnosis year (1-year periods) multiplied by person-years of follow-up. We computed standardised incidence ratios (SIRs) for BC as the ratio of observed to expected cancers, overall, and at 1, 1--5, and \>5 years ([@bib18]). We stratified results by age at conisation, year of conisation, comorbid diseases, and CCI (excluding cancer diagnoses) ([Supplementary Appendix 2](#sup1){ref-type="supplementary-material"}). In a subgroup analysis, we computed BC risk according to ER status, and BC stage at diagnosis. This study was approved by the Danish Data Protection Agency (\#1-16-02-1-08).

Results
=======

Overall, 87 782 women underwent conisation in 1978--2013; 90% were aged \<50 years at conisation (median age=33.8 years, interquartile range: 28.3--41.1 years). Most patients had no comorbidities (CCI=0); 3% had autoimmune disease or obesity, and 2% had alcohol-related disease ([Table 1](#tbl1){ref-type="table"}).

Women who underwent conisation had increased BC risk (SIR=1.1, 95% CI=1.0--1.1, and absolute risk of 7.7%, 95% CI=7.3--8.1%) over a maximum follow-up of 35.9 years (median=15.5, interquartile range: 7.9--24.1 years). BC risk increased with age at conisation up to age 70 years, with highest SIRs among women aged 50--69 years (SIR=1.2, 95% CI=1.1--1.3). BC risk was elevated in the first 5 years of follow-up (\<1 year of follow-up: SIR=1.2, 95% CI=0.92--1.5; 1--5 years of follow-up: SIR=1.2, 95% CI=1.1--1.3), attenuating thereafter (⩾5 years follow-up: SIR=1.1, 95% CI=1.0--1.1). Stratified analyses revealed no effect modification by CCI, obesity, or alcohol diagnoses, but increased BC risk associated with autoimmune disease especially after 5 years of follow-up (SIR=1.4, 95% CI=1.0--1.8) ([Table 2](#tbl2){ref-type="table"}). The risk of localised BC remained slightly elevated throughout follow-up; that of non-localised disease was elevated only up to 5 years after conisation. The results of analyses stratified by ER status (1997--2013) indicated increased risk of ER positive BC, but not ER negative disease, or, of BCs with unknown ER status, regardless of follow-up time. We observed similar findings in sensitivity analyses including inpatients and outpatients ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}).

Discussion
==========

Our large population-based cohort study suggests slightly elevated BC risk associated with a history of cervical conisation. Among women diagnosed with local stage breast tumours, risk remained elevated regardless of follow-up time. Our findings may therefore be partly attributable to more intense disease surveillance, that is, women who undergo conisation are more likely to avail themselves of other cancer screening procedures, such as mammography ([@bib8]; [@bib3]). In addition, BC risk increased with longer follow-up, particularly among women with a history of autoimmune disease.

The increased BC risk among women with a history of autoimmune disease is intriguing, and counters the perception that autoimmune disease correlates with decreased BC incidence ([@bib9]). However, our finding may reflect reports of an increased risk of cervical dysplasia/cancer among individuals with autoimmune disease ([@bib12]). The mechanisms underlying this association are unclear but could involve increased healthcare contact among patients with autoimmune conditions. The observed association also may reflect use of immunosuppressive drugs or steroids---indicated for autoimmune disease---which may facilitate HPV immunoevasion. However, our previous research suggests no association between glucocorticoid use and BC risk ([@bib24], [@bib23]). Our findings provide important rationale to promote uptake of the HPV vaccine among women with autoimmunities ([@bib12]).

The increased BC risk among those younger at conisation may be due to heightened screening. However, it may also reflect findings by Lawson *et al* ([@bib14]), where BC patients with a history of cervical cancer were on average 10 years younger at BC diagnosis than those without cervical cancer.

Strengths of our study include its population-based design in a country with unfettered access to healthcare and complete follow-up. Data were prospectively collected for administrative purposes, minimising bias. The completeness of BC diagnoses in the DCR and the Danish Pathology Registry approaches 100% ([@bib26]; [@bib6]). Use of personal identity numbers facilitated individual-level data linkage across the registries ([@bib22]). We observed little difference after stratifying by alcohol-related diagnoses and obesity, so confounding due to such factors seems unlikely.

The Norwegian registry-based study ([@bib8]), observed a 10--50% increased BC risk in women with precancerous cervical lesions, which they attributed to detection bias, as they observed no increased risk of metastatic BC. Our study extends this research incorporating information on comorbidities and hormone receptor status.

The validity of our estimates depends on several factors. We had information on outpatient conisation from 1995, thus our study is prone to non-differential misclassification of conisation between 1978 and 1995. However, a sensitivity analysis restricted to the cohort who underwent conisation from 1995 onwards yielded similar findings. We had no information on HPV subtype, which may modify BC risk ([@bib5]). However, the oncogenic HPV subtypes (16, 18, 33, and 35) are those most likely to lead to persistent infection, for which conisation is indicated in Denmark. We lacked information on parity. Multi-parity correlates with increased cervical cancer risk ([@bib11]), but with decreased BC risk (depending on age at first birth) ([@bib17]). Thus adjusting for parity may attenuate our findings.

BC imposes a substantial burden on health and health services. Contrary to the three- to six-fold increased risk of BC associated with HPV infection observed in meta-analyses ([@bib15]; [@bib21]; [@bib28]), our findings suggest a long-term slight increase in BC risk among women with a history of chronic HPV infection. Priorities for future research involve evaluating the association of HPV subtypes with BC risk and investigating the incidence of BC among individuals vaccinated for HPV.
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###### 

Click here for additional data file.

###### Baseline characteristics of the cohort of women who underwent conisation in Denmark between 1978 through 2013

  **Characteristic**                      ***n***   **%**
  -------------------------------------- --------- -------
  Total study population                  87 782    100.0
  **Age at conisation (years)**                    
  18--29                                  28 786     33
  30--49                                  50 638     58
  50--69                                   7652       9
  ⩾70                                       706      0.8
  **Year of conisation**                           
  1978--1982                              11 727     13
  1983--1987                              10 803     12
  1988--1992                              11 973     14
  1993--1997                              12 677     14
  1998--2002                              13 584     15
  2003--2007                              12 354     14
  2008--2013                              14 664     17
  **Charlson Comorbidity Index score**             
  Low (0)                                 81 523     93
  Moderate (1--2)                          5727       7
  Severe (⩾3)                               532      0.6
  **Autoimmune disease**                           
  No                                      84 882     97
  Yes                                      2900       3
  **Obesity diagnosis**                            
  No                                      85 341     97
  Yes                                      2441       3
  **Alcohol-related disease**                      
  No                                      85 871     98
  Yes                                      1911       2

###### Standardised incidence ratios of breast cancer among women who underwent conisation in Denmark between 1978 through 2013 according to follow-up time

                                **Overall**   **\<1 year**       **1**--**5 years**   **\>5 years**                                     
  ----------------------------- ------------- ------------------ -------------------- ------------------ ----- ----------------- ------ ------------------
  Overall                       2694          1.1 (1.0, 1.1)     71                   1.2 (0.92, 1.5)    334   1.2 (1.1, 1.3)    2289   1.1 (1.0, 1.1)
  Age at conisation (years)                                                                                                              
   0--29                        401           1.0 (0.94, 1.2)    4                    2.5 (0.68, 6.4)    18    1.4 (0.84, 2.2)   379    1.0 (0.92, 1.1)
   30--49                       1870          1.1 (1.0, 1.1)     45                   1.3 (0.92, 1.7)    208   1.2 (1.0, 1.3)    1617   1.0 (0.99, 1.1)
   50--69                       405           1.2 (1.0, 1.3)     21                   1.0 (0.63, 1.6)    99    1.3 (1.0, 1.5)    285    1.1 (1.0, 1.3)
   70+                          18            0.89 (0.53, 1.4)   1                    0.45 (0.01, 2.5)   9     1.2 (0.57, 2.4)   8      0.74 (0.32, 1.5)
  Year of conisation                                                                                                                     
   1978--1982                   819           1.1 (1.0, 1.2)     7                    1.0 (0.42, 2.1)    38    1.1 (0.78, 1.5)   774    1.1 (1.0, 1.2)
   1983--1987                   571           1.0 (0.94, 1.1)    8                    1.2 (0.52, 2.4)    37    1.1 (0.76, 1.5)   526    1.0 (0.93, 1.1)
   1988--1992                   491           1.0 (0.92, 1.1)    10                   1.1 (0.54, 2.1)    47    1.1 (0.81, 1.5)   434    1.0 (0.90, 1.1)
   1993--1997                   379           1.1 (0.96, 1.2)    8                    0.86 (0.37, 1.7)   50    1.1 (0.80, 1.4)   321    1.1 (0.95, 1.2)
   1998--2002                   248           1.1 (0.94, 1.2)    14                   1.4 (0.79, 2.4)    60    1.3 (0.95, 1.6)   174    1.0 (0.86, 1.2)
   2003--2007                   136           1.3 (1.1, 1.5)     10                   1.2 (0.59, 2.3)    67    1.5 (1.2, 2.0)    59     1.1 (0.85, 1.5)
   2008--2013                   50            1.2 (0.92, 1.6)    14                   1.3 (0.68, 2.1)    35    1.3 (0.87, 1.7)   1      0.78 (0.02, 4.3)
  Charlson Comorbidity Index                                                                                                             
   Low (CCI=0)                  2560          1.1 (1.0, 1.1)     61                   1.2 (0.88, 1.5)    304   1.2 (1.1, 1.4)    2195   1.1 (1.0, 1.1)
   Medium (CCI=1--2)            126           1.1 (0.91, 1.3)    10                   1.5 (0.72, 2.8)    28    1.1 (0.74, 1.6)   88     1.1 (0.85, 1.3)
   High (⩾3)                    8             0.93 (0.40, 1.8)   0                                       2     0.70 (0.1, 2.5)   6      1.2 (0.46, 2.7)
  Autoimmune disease                                                                                                                     
   No                           2629          1.1 (1.0, 1.1)     65                   1.1 (0.87, 1.4)    323   1.2 (1.1, 1.4)    2241   1.0 (1.0, 1.1)
   Yes                          65            1.3 (1.0, 1.7)     6                    2.2 (0.80, 4.7)    11    1.0 (0.51, 1.8)   48     1.4 (1.0, 1.8)
  Obesity diagnosis                                                                                                                      
   No                           2674          1.1 (1.0, 1.1)     70                   1.2 (0.92, 1.5)    329   1.2 (1.1, 1.3)    2275   1.1 (1.0, 1.1)
   Yes                          20            0.88 (0.54, 1.4)   1                    0.51 (0.01, 2.9)   5     1.9 (0.93, 3.6)   14     1.1 (0.65, 1.7)
  Alcohol-related disease                                                                                                                
   No                           2667          1.1 (1.0, 1.1)     70                   1.2 (0.92, 1.5)    324   1.2 (1.1, 1.3)    2270   1.1 (1.0, 1.1)
   Yes                          30            1.3 (0.84, 1.8)    1                    0.76 (0.02, 4.2)   10    1.9 (0.93, 3.6)   19     1.1 (0.65, 1.7)
  Oestrogen receptor positive   377           1.2 (1.1, 1.3)     27                   1.4 (0.90, 2.0)    121   1.4 (1.2, 1.7)    229    1.1 (0.99, 1.3)
  Oestrogen receptor negative   75            0.94 (0.74, 1.2)   3                    0.49 (0.10, 1.4)   29    1.1 (0.76, 1.6)   43     0.89 (0.64, 1.2)
  Localised breast cancer       1414          1.1 (1.1, 1.2)     35                   1.2 (0.84, 1.7)    170   1.3 (1.1, 1.5)    1209   1.1 (1.1, 1.2)
  Non-localised breast cancer   1144          1.0 (0.94, 1.1)    32                   1.1 (0.78, 1.6)    155   1.2 (1.0, 1.4)    957    0.97 (0.91, 1.0)

Abbreviations: CCI=Charlson Comorbidity Index; SIR=standardised incidence ratio.
